Leveraging MGB’s Clinical and Scientific Discovery Engine to Benefit Communities Around the World
Why It Matters
The talk shows how integrated clinical research at an academic medical center can turn mechanistic insights into tools for early detection, targeted treatment and global prevention of brain disease, potentially lowering dementia, stroke and depression burden worldwide. Continued investment in such translational ecosystems is critical to convert promising biomarkers and interventions into scalable public‑health impact.
Summary
Dr. Jonathan Rosand, a neurology leader at Mass General Brigham and Harvard, outlined how an academic medical center’s clinical and scientific engine drives discovery across neurocritical care, stroke genetics, recovery and prevention. Framing his talk around six guiding questions, he described early work on blood-pressure management and CT biomarkers in intracerebral hemorrhage, the shift from difficult acute-stage studies to more tractable chronic and genetic investigations, and efforts to reduce recurrent stroke, cognitive decline and psychiatric sequelae. Rosand highlighted translational successes like the CTA “spot sign,” the brain care score, and the Global Brain Health Coalition as examples of multidisciplinary, international collaboration. He emphasized the unique capacity of academic centers to iterate on high‑risk research, train talent, and translate findings into population-level prevention strategies.
Comments
Want to join the conversation?
Loading comments...